Compare Mercadolibre Inc (MELI) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mercadolibre Inc vs Tango Therapeutics Inc. — how do they compare? Mercadolibre Inc trades at $1,823.88 (market cap $93.24B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Mercadolibre Inc is far larger — about 24.9× Tango Therapeutics Inc.'s market cap, and Mercadolibre Inc is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mercadolibre Inc for 118 Days and Tango Therapeutics Inc. for 0 Days on average.
| MELI | TNGX | |
|---|---|---|
Market Cap | $93.24B | $3.74B |
Volume | 380,071 | 3,438,781 |
Sector | Consumer Cyclical | Health |
52-Week High | $2.36K | $32.90 |
52-Week Low | $1.55K | $7.50 |
Typical Hold Time | 118 Days | 0 Days |
Enterprise Value | $100.88B | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MercadoLibre (MELI) trades at $1,876.04, down 0.87% on the day, with strong technical bullish signals from moving averages. The company demonstrates robust revenue growth, reaching $28.89 billion in 2025, though net income margin declined to 6.91%. Recent news highlights expansion in Brazil with one-hour delivery services and growing fintech credit portfolio, while analyst consensus remains strongly bullish with a $2,160 price target.
MELI presents a compelling growth story in Latin American e-commerce and fintech, supported by expanding market share and ecosystem integration. Key risks include macroeconomic pressures in Argentina and margin compression despite revenue growth. With 73% analyst buy ratings and institutional accumulation, the stock offers upside potential but requires monitoring of profitability trends and regional economic stability.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
